Analysis of Long-term (Investment) Activity Ratios
Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Long-term Activity Ratios (Summary)
Illumina Inc., long-term (investment) activity ratios
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Illumina Inc. net fixed asset turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 and from 2019 to 2020. |
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Illumina Inc. total asset turnover ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Illumina Inc. equity turnover ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |
Net Fixed Asset Turnover
Illumina Inc., net fixed asset turnover calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Property and equipment, net | 922) | 889) | 1,075) | 931) | 713) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover1 | 3.51 | 3.99 | 3.10 | 2.96 | 3.36 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 8.73 | 11.23 | — | — | — | |
| Amgen Inc. | 4.96 | 4.51 | — | — | — | |
| Bristol-Myers Squibb Co. | 7.22 | 4.18 | — | — | — | |
| Danaher Corp. | 6.83 | 7.78 | — | — | — | |
| Eli Lilly & Co. | 2.83 | 2.83 | — | — | — | |
| Gilead Sciences Inc. | 4.90 | 4.91 | — | — | — | |
| Johnson & Johnson | 4.40 | 4.65 | — | — | — | |
| Merck & Co. Inc. | 2.67 | 3.11 | — | — | — | |
| Pfizer Inc. | 3.01 | 3.71 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.64 | 2.72 | — | — | — | |
| Thermo Fisher Scientific Inc. | 5.45 | 5.38 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 6.47 | 5.59 | — | — | — | |
| Net Fixed Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 4.30 | — | — | — | — | |
| Net Fixed Asset Turnover, Industry | ||||||
| Health Care | 9.23 | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Net fixed asset turnover = Revenue ÷ Property and equipment, net
= 3,239 ÷ 922 = 3.51
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover | An activity ratio calculated as total revenue divided by net fixed assets. | Illumina Inc. net fixed asset turnover ratio improved from 2018 to 2019 but then slightly deteriorated from 2019 to 2020 not reaching 2018 level. |
Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset)
Illumina Inc., net fixed asset turnover (including operating lease, right-of-use asset) calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Property and equipment, net | 922) | 889) | 1,075) | 931) | 713) | |
| Operating lease right-of-use assets | 532) | 555) | —) | —) | —) | |
| Property and equipment, net (including operating lease, right-of-use asset) | 1,454) | 1,444) | 1,075) | 931) | 713) | |
| Long-term Activity Ratio | ||||||
| Net fixed asset turnover (including operating lease, right-of-use asset)1 | 2.23 | 2.45 | 3.10 | 2.96 | 3.36 | |
| Benchmarks | ||||||
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Competitors2 | ||||||
| AbbVie Inc. | 7.46 | 10.06 | — | — | — | |
| Amgen Inc. | 4.58 | 4.11 | — | — | — | |
| Bristol-Myers Squibb Co. | 6.30 | 3.76 | — | — | — | |
| Danaher Corp. | 5.30 | 5.84 | — | — | — | |
| Eli Lilly & Co. | 2.63 | 2.66 | — | — | — | |
| Gilead Sciences Inc. | 4.34 | 4.28 | — | — | — | |
| Johnson & Johnson | 4.18 | 4.41 | — | — | — | |
| Merck & Co. Inc. | 2.43 | 2.90 | — | — | — | |
| Pfizer Inc. | 2.74 | 3.39 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 2.58 | 2.66 | — | — | — | |
| Thermo Fisher Scientific Inc. | 4.82 | 4.69 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 4.83 | 5.00 | — | — | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 3.90 | — | — | — | — | |
| Net Fixed Asset Turnover (including Operating Lease, Right-of-Use Asset), Industry | ||||||
| Health Care | 7.23 | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Net fixed asset turnover (including operating lease, right-of-use asset) = Revenue ÷ Property and equipment, net (including operating lease, right-of-use asset)
= 3,239 ÷ 1,454 = 2.23
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Net fixed asset turnover (including operating lease, right-of-use asset) | An activity ratio calculated as total revenue divided by net fixed assets (including operating lease, right-of-use asset). | Illumina Inc. net fixed asset turnover ratio (with operating lease, right-of-use asset) deteriorated from 2018 to 2019 and from 2019 to 2020. |
Total Asset Turnover
Illumina Inc., total asset turnover calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Total assets | 7,585) | 7,316) | 6,959) | 5,257) | 4,281) | |
| Long-term Activity Ratio | ||||||
| Total asset turnover1 | 0.43 | 0.48 | 0.48 | 0.52 | 0.56 | |
| Benchmarks | ||||||
| Total Asset Turnover, Competitors2 | ||||||
| AbbVie Inc. | 0.30 | 0.37 | — | — | — | |
| Amgen Inc. | 0.39 | 0.37 | — | — | — | |
| Bristol-Myers Squibb Co. | 0.36 | 0.20 | — | — | — | |
| Danaher Corp. | 0.29 | 0.29 | — | — | — | |
| Eli Lilly & Co. | 0.53 | 0.57 | — | — | — | |
| Gilead Sciences Inc. | 0.36 | 0.36 | — | — | — | |
| Johnson & Johnson | 0.47 | 0.52 | — | — | — | |
| Merck & Co. Inc. | 0.52 | 0.55 | — | — | — | |
| Pfizer Inc. | 0.27 | 0.31 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.50 | 0.53 | — | — | — | |
| Thermo Fisher Scientific Inc. | 0.47 | 0.44 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 0.53 | 0.50 | — | — | — | |
| Total Asset Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 0.39 | — | — | — | — | |
| Total Asset Turnover, Industry | ||||||
| Health Care | 0.68 | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Total asset turnover = Revenue ÷ Total assets
= 3,239 ÷ 7,585 = 0.43
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Total asset turnover | An activity ratio calculated as total revenue divided by total assets. | Illumina Inc. total asset turnover ratio improved from 2018 to 2019 but then deteriorated significantly from 2019 to 2020. |
Equity Turnover
Illumina Inc., equity turnover calculation, comparison to benchmarks
| Dec 31, 2020 | Dec 29, 2019 | Dec 30, 2018 | Dec 31, 2017 | Dec 31, 2016 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Revenue | 3,239) | 3,543) | 3,333) | 2,752) | 2,398) | |
| Total Illumina stockholders’ equity | 4,694) | 4,613) | 3,758) | 2,749) | 2,197) | |
| Long-term Activity Ratio | ||||||
| Equity turnover1 | 0.69 | 0.77 | 0.89 | 1.00 | 1.09 | |
| Benchmarks | ||||||
| Equity Turnover, Competitors2 | ||||||
| AbbVie Inc. | 3.50 | — | — | — | — | |
| Amgen Inc. | 2.58 | 2.30 | — | — | — | |
| Bristol-Myers Squibb Co. | 1.12 | 0.51 | — | — | — | |
| Danaher Corp. | 0.56 | 0.59 | — | — | — | |
| Eli Lilly & Co. | 4.35 | 8.56 | — | — | — | |
| Gilead Sciences Inc. | 1.34 | 0.98 | — | — | — | |
| Johnson & Johnson | 1.31 | 1.38 | — | — | — | |
| Merck & Co. Inc. | 1.90 | 1.81 | — | — | — | |
| Pfizer Inc. | 0.66 | 0.82 | — | — | — | |
| Regeneron Pharmaceuticals Inc. | 0.77 | 0.71 | — | — | — | |
| Thermo Fisher Scientific Inc. | 0.93 | 0.86 | — | — | — | |
| Vertex Pharmaceuticals Inc. | 0.71 | 0.68 | — | — | — | |
| Equity Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | 1.22 | — | — | — | — | |
| Equity Turnover, Industry | ||||||
| Health Care | 1.99 | — | — | — | — | |
Based on: 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-29), 10-K (reporting date: 2018-12-30), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31).
1 2020 Calculation
Equity turnover = Revenue ÷ Total Illumina stockholders’ equity
= 3,239 ÷ 4,694 = 0.69
2 Click competitor name to see calculations.
| Long-term activity ratio | Description | The company |
|---|---|---|
| Equity turnover | An activity ratio calculated as total revenue divided by shareholders’ equity. | Illumina Inc. equity turnover ratio deteriorated from 2018 to 2019 and from 2019 to 2020. |